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Introduction: Decreased production of cathelicidin antimicrobial protein-18 (hCAP18) has been proposed to be a
key mechanism linking decreased 25-hydroxyvitamin D (25D) levels with adverse outcomes among critically ill
patients. However, few studies in humans have directly assessed plasma hCAP18 levels, and no study has evaluated
the association between hCAP18 levels and adverse outcomes among critically ill patients.
Methods: We performed a single-center, prospective cohort study among 121 critically ill patients admitted to
intensive care units (ICUs) between 2008 and 2012. We measured plasma hCAP18, 25D, D-binding protein, and
parathyroid hormone levels on ICU day 1. The primary endpoint was 90-day mortality. Secondary endpoints
included hospital mortality, sepsis, acute kidney injury, duration of mechanical ventilation, and hospital length
of stay.
Results: ICU day 1 hCAP18 levels were directly correlated with 25D levels (Spearman’s rho (rs) = 0.30, P = 0.001). In
multivariate analyses adjusted for age and Acute Physiology and Chronic Health Evaluation II (APACHE II) score,
patients with hCAP18 levels in the lowest compared to highest tertile on ICU day 1 had a 4.49 (1.08 to 18.67)
greater odds of 90-day mortality, and also had greater odds of sepsis. ICU day 1 levels of other analytes were not
associated with 90-day mortality.
Conclusions: Lower 25D levels on ICU day 1 are associated with lower hCAP18 levels, which are in turn associated
with a greater risk of 90-day mortality. These findings provide a potential mechanistic basis for the frequently
observed association between low 25D levels and poor outcomes in critically ill patients.Introduction
Vitamin D deficiency/insufficiency is very common in
critically ill patients, with reported rates ranging from
81.5% to 99% [1-3]. Further, multiple studies have docu-
mented associations between decreased 25-hydroxyvitamin
D (25D) levels and increased risk of adverse outcomes
including prolonged length of stay [3], infection [4], acute
kidney injury (AKI) [5], and mortality [3-7]. These associa-
tions are often attributed to the effects of vitamin D metab-
olites on host defense, which have been well characterized
in vitro [8-10]. However, few studies in humans have sim-
ultaneously evaluated 25D levels together with markers of
host defense in critically ill patients.
The strongest known link between vitamin D meta-
bolites and the immune system relates to the effects of
vitamin D metabolites on the production of cathelicidins* Correspondence: deleaf@partners.org
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unless otherwise stated.[10], a critical family of antimicrobial proteins. Cathelici-
dins act by disrupting foreign-cell membranes, binding
lipopolysaccharide residues, and recruiting leukocytes
[11,12]. In animal models, deficiency of cathelicidin is
associated with increased susceptibility to bacterial infec-
tion [13-15], whereas overexpression confers protection
[16]. In humans, cathelicidin antimicrobial protein-18
(hCAP18) is the only known cathelicidin. hCAP18 is
found primarily in the granules of neutrophils, and is
also produced and secreted by monocytes, macrophages,
epithelial cells, and other cell types [17]. Low 25D levels
are associated with reduced production of hCAP18 by
macrophages infected with Mycobacterium tuberculosis,
whereas treatment with the activated vitamin D metab-
olite 1,25-dihydroxyvitamin D (1,25D) in vitro results in
enhanced production of hCAP18 and improved killing
of the microorganisms [10]. In addition to macrophages,
the in vitro inducibility of hCAP18 by 25D and 1,25Dis is an Open Access article distributed under the terms of the Creative
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lines [10,18-22].
Despite the strong link between vitamin D metabolites
and hCAP18 demonstrated in preclinical models, no
study to our knowledge has measured plasma hCAP18
levels and evaluated their association with adverse out-
comes in critically ill patients. Additionally, conflicting
results have been reported on the association between
plasma hCAP18 and 25D levels in humans [23-25]. We
hypothesized that 25D and hCAP18 levels are directly
correlated in critically ill patients, and that lower hCAP18
levels are associated with increased risk of 90-day mortality.
Materials and methods
Study design
We conducted a prospective cohort study among patients
admitted to intensive care units (ICUs) at Brigham and
Women’s Hospital between 2008 and 2012. Patients or
their surrogates provided written informed consent and
all protocols were approved by the Partners Human
Research Committee (protocol #2007P000894), which
is the Institutional Review Board for Brigham and Women’s
Hospital.
Inclusion criteria were age ≥18 years and admission to
a medical or surgical ICU. Exclusion criteria were: (1)
anticipated ICU stay <24 hours; (2) admitted to the ICU
for a low-risk condition such as airway monitoring; (3)
serum creatinine >4.5 mg/dl or receiving dialysis; (4) preg-
nancy; and (5) institutionalized individuals.
We collected venous blood samples daily on ICU days
1 through 5. Blood samples were collected into EDTA-
containing vacutainers, centrifuged at 3,200 RPM for
15 minutes, and the plasma was aliquoted and stored
at −80°C within 2 hours of collection. We measured
analytes in plasma samples at two time points: within
24 hours of ICU arrival and 48 hours later (hereafter
referred to as ICU day 1 and 3, respectively).
Clinical outcomes
Investigator DEL adjudicated all outcomes by reviewing
discharge summaries and progress notes, and was blinded
to all study measurements at the time of adjudication. The
primary endpoint was 90-day mortality. Secondary end-
points were hospital mortality, sepsis, incident AKI, dur-
ation of mechanical ventilation, and hospital length of
stay. The association between hCAP18 levels and sepsis
was assessed cross-sectionally since many of the patients
already met sepsis criteria upon arrival to the ICU. Other
outcomes were assessed prospectively.
Sepsis was defined according to consensus defin-
ition [26]. Incident AKI was defined according to serum
creatinine-based criteria established by the Kidney Disease
Improving Global Outcomes Work Group [27]. Patients
who already had AKI (N = 4) on arrival to the ICU wereexcluded from analyses of incident AKI. Duration of
mechanical ventilation and hospital length of stay were
assessed using ventilator-free days and hospital-free days
to avoid the confounding effect of mortality. Ventilator-
free days and hospital-free days were defined as 28 minus
the number of ventilator-dependent days or hospitali-
zation days, respectively, assuming survival to 28 days or
discharge from the hospital. Patients who died before
28 days were assigned a score of zero [28,29]. In explora-
tory analyses, we also assessed whether hCAP18 levels on
ICU day 1 differed by sepsis severity, primary type of
infection, or primary organism.Laboratory measurements
All biomarkers were measured on ICU days 1 and 3 ex-
cept parathyroid hormone (PTH), which was mea-
sured on ICU day 1 only. Assays were performed at
the Harvard Medical School Clinical and Translational
Science Award core laboratory. Plasma hCAP18 levels
were measured by enzyme-linked immunosorbent assay
(ELISA) using a commercially available kit (Hycult
Biotech, Uden, Netherlands) which recognizes the 37
amino acid biologically active C-terminal fragment
(LL-37) cleaved from hCAP18 [30]. Plasma 25D (combined
D2 and D3, hereafter referred to as ‘total 25D’) and D-
binding protein (DBP) levels were measured by ELISA
using commercially available kits (Abbott Laboratories,
Abbott Park, IL, USA and R&D Systems, Inc., Minneapolis,
MN, USA, respectively). Plasma intact PTH was measured
using a chemiluminescent immunoassay (Beckman Coulter,
Fullerton, CA, USA). Interassay coefficients of variation,
estimated using blinded replicate samples from ICU pa-
tients, were 5.5% for hCAP18, 3.5% for total 25D, 11% for
DBP, and 3.1% for PTH.Bioavailable and free 25D
Because total 25D circulates bound to DBP (85 to 90%)
and albumin (10 to 15%), less than 1% of circulating hor-
mone exists in its free form [31]. The sum of free- and
albumin-bound hormone is often referred to as ‘bioavail-
able’, because 25D bound to DBP is thought to have lim-
ited biological activity. In the absence of commercially
available assays to directly measure bioavailable and free
25D levels, most studies have relied on formulas that
incorporate binding coefficients for DBP and albumin,
coupled to measurement of total 25D, DBP, and albumin
levels [31-33]. Using these formulas, bioavailable com-
pared to total 25D levels are more strongly associated
with bone mineral density among young healthy adults
[32]; serum calcium and PTH levels among incident
hemodialysis patients [34]; and mortality among hos-
pitalized patients [35]. We therefore used these equa-
tions to estimate bioavailable and free 25D levels. The
Table 1 Baseline characteristics
N = 121
Demographics
Age (yr) - median (IQR) 62 (56-73)
Female sex (%) 46 (38)
White race (%) 112 (93)
Comorbidities (%)
Hypertension 64 (53)
Chronic lung disease 37 (31)
Active malignancy 34 (28)
Diabetes mellitus 29 (24)
Chronic kidney disease 7 (6)
Congestive heart failure 4 (3)
Chronic liver disease 2 (2)
Severity of illness
APACHE II score - median (IQR)* 14 (10-16)








Status of procedure (for surgical patients) (%)
Elective 41 (34)
Urgent 57 (47)
Days in hospital prior to enrollment – median (IQR) 1 (1-3)
*APACHE II, Acute Physiology and Chronic Health Evaluation II, is an ICU
severity of illness scoring system ranging from 0 to 71, with higher scores
corresponding to more severe disease; †Charlson Comorbidity Index is a
prognostic tool that has been validated in critically ill patients, with higher
scores indicating worse prognosis [37]. IQR, interquartile range; ICU, intensive
care unit; SICU, surgical/trauma ICU; TICU, thoracic ICU; CCU, cardiac care unit;
MICU, medical ICU.
Table 2 hCAP18 and mineral metabolite/hormone levels on IC
Biomarker Reference range ICU d
hCAP18 (ng/ml) Undefined 160 (
Total 25D (ng/ml) 30-80 17 (1
Bioavailable 25D (ng/ml) Undefined 2.5 (1
Free 25D (pg/ml) Undefined 9.6 (6
DBP (mg/dl) 20-55 12.7 (
Albumin (g/dl) 4.1-5.3 3.1 (2
PTH (pg/ml) 15-65 40 (2
Values represent median (25th to 75th interquartile range). †Fewer samples were ava
hCAP18, human cathelicidin antimicrobial protein-18; 25D, 25-hydroxyvitamin D; DB
Leaf et al. Critical Care  (2015) 19:80 Page 3 of 9equations used to calculate these levels are provided
in Additional file 1.
Statistical analyses
Statistical analysis was performed with SAS Version 9.3
(SAS Institute Inc., Cary, NC, USA). Correlations be-
tween hCAP18 levels with total 25D, bioavailable 25D,
free 25D, and PTH levels on ICU day 1 were assessed
using Spearman’s rank correlation coefficient. Comparison
of biomarker levels between patients who were alive vs.
dead at 90 days was assessed using the Wilcoxon rank
sum test. Comparison of biomarker levels over time
(ICU day 1 vs. day 3) was assessed using the Wilcoxon
signed-rank test. Differences in hCAP18 levels on ICU
day 1 on the basis of sepsis severity, primary type of
infection, and primary organism were assessed using the
Kruskal-Wallis test.
Logistic regression was used to assess the association
between tertiles of biomarker levels on ICU day 1 and
90-day mortality (the primary outcome) as well as hos-
pital mortality, sepsis, and AKI (secondary outcomes).
The highest tertile served as the reference group. Mul-
tivariable models included age and acute physiology and
chronic health evaluation (APACHE II) score, calculated
on ICU day 1. In exploratory analyses we also adjusted
for ICU day 1 estimated glomerular filtration rate
(eGFR), calculated using the chronic kidney disease epi-
demiology equation [36], since reduced kidney function
could affect hCAP18 levels. Tertiles of biomarker levels
on ICU day 1 and 90-day mortality were also assessed in
aggregate using the Cochran-Armitage test for trend.
The association between hCAP18 levels on ICU day 1
and ventilator-free days and hospital-free days was
assessed using Spearman’s rank correlation coefficient. All
comparisons are two-tailed, with P <0.05 considered
significant.
Results
We enrolled and collected samples from 121 patients.
Median (interquartile range (IQR)) age was 62 (56 to 73)
years. The most common comorbidities were hypertensionU days 1 and 3
ay 1 (N = 121) ICU day 3 (N = 111)† P value
106-286) 166 (116-291) 0.92
3-22) 17 (14-21) 0.42
.8-3.5) 2.4 (1.6-3.3) 0.24
.5-12.9) 9.5 (6.5-12.9) 0.98
9.4-17.1) 13.7 (10.1-17.1) 0.27
.4-3.5) 2.9 (2.3-3.3) 0.002
8-56) --- N/A
ilable on ICU day 3 due to interim death or discharge. ICU, intensive care unit;






















































































Figure 1 Correlations between plasma hCAP18, 25D metabolites, and PTH. Total 25D represents the sum of all 25-hydroxyvitamin D (both
D2 and D3), including 25D bound to DBP, albumin, and circulating freely; bioavailable 25D is the sum of albumin-bound and free 25D; free 25D is
the circulating fraction of 25D that is neither bound to DBP nor albumin. DBP, D-binding protein; hCAP18, human cathelicidin antimicrobial
protein-18; PTH, parathyroid hormone.




Severe sepsis 30 (42)
Septic shock 17 (24)
Primary site of infection
Respiratory 35 (49)
Abscess or necrotizing fasciitis 13 (18)
Gastrointestinal/peritonitis 12 (17)
Unknown or other† 11 (16)
Primary organism
Staphylococcus aureus 14 (20)
Other Gram(+)‡ 13 (18)
Pseudomonas, Klebsiella, Escherichia coli, and Enterobacter 15 (21)
Other Gram(−)¶ 8 (11)
Unknown or other§ 21 (30)
Values represent n (%). †Includes bacteremia (N = 5), urosepsis (N = 2),
pericarditis (N = 1), and septic arthritis (N = 1); ‡includes Enterococus (N = 7),
Lactobacillus (N = 2), coagulase-negative Staphylococcus (N = 2), Streptococcus
pneumoniae (N = 1), and Streptococcus mitis (N = 1); ¶includes Proteus mirabilis
(N = 2), Serratia (N = 2), Citrobacter (N = 1), Moraxella catarrhalis (N = 1),
Fusobacterium necrophorum (N = 1), and Hemophilus influenza (N = 1);
§includes Clostridium difficile (N = 3) and Aspergillus (N = 1).
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(28%). The majority of patients (84%) were admitted to
a surgical ICU. Additional baseline characteristics are
shown in Table 1.
hCAP18 and vitamin D markers
Table 2 shows plasma levels of hCAP18, total 25D, bio-
available 25D, and free 25D, DBP, albumin, and PTH
from ICU days 1 and 3. Levels of total 25D on ICU day
1 were <20 ng/ml in 68% of patients and <30 ng/ml in
95% of patients. Other than albumin, which declined
over time, plasma levels of other biomarkers were un-
changed between ICU days 1 and 3.
Factors associated with hCAP18 levels
Plasma hCAP18 levels on ICU day 1 correlated positively
with total 25D (Spearman’s rho (rs) = 0.30, P = 0.001)
but not with bioavailable 25D, free 25D, or PTH
levels (Figure 1). Plasma hCAP18 levels on ICU day 1
did not differ by age, gender, type of ICU (surgical vs.
nonsurgical), or status of procedure (urgent vs. elect-
ive). Similarly, plasma hCAP18 levels on ICU day 1
did not differ by comorbidities except for active ma-
lignancy (median (IQR) 120 (78 to 174) and 186 (116
to 304) ng/ml for patients with vs. without active ma-
lignancy, P = 0.002). Additionally, we found no cor-
relation between hCAP18 levels and eGFR on ICU day 1
(Additional file 2).
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Among the 121 participants, 71 (59%) had sepsis, 9 (7%)
died in the hospital, and 21 (17%) died within 90 days.
Data on sepsis severity, primary site of infection, and
primary organism for the 71 patients who developed
sepsis are shown in Table 3. Plasma hCAP18 levels on
ICU day 1 did not differ by sepsis severity (P = 0.14),
primary site of infection (P = 0.23), or primary organism
(P = 0.07) (Additional file 3).
Biomarker levels on ICU days 1 and 3 in patients who
were alive vs. dead at 90 days are shown in Figure 2.
Plasma hCAP18 levels on ICU day 1 were lower in
patients who died compared to patients who survived
(median (IQR) 116 (88 to 178) and 176 (112 to 304)
ng/ml, P = 0.04). Additionally, free 25D levels on ICU
day 3 were lower in patients who died compared to
patients who survived (median (IQR) 7.7 (5.9 to 9.3) and
9.9 (7.0 to 13.1), P = 0.03). Other biomarker levels were
similar between survivors vs. nonsurvivors.
In univariate analyses, patients with ICU day 1 hCAP18
levels in the lowest vs. highest tertile had a significantly
greater risk of 90-day mortality (Table 4). AfterFigure 2 Plasma hCAP18, 25D metabolites, and PTH levels among surviv
(B) Biomarker levels on ICU day 3. *P <0.05, comparison of biomarker levels am
interquartile range). 25D, 25-hydroxyvitamin D; hCAP18, human cathelicidin anadjusting for age and APACHE II score, the association
was slightly attenuated but remained significant
(adjusted odds ratio = 4.49, 95% confidence interval =
1.08 to 18.67, P = 0.04). In exploratory analyses, further
adjustment for ICU day 1 eGFR did not affect the asso-
ciation (adjusted odds ratio = 4.44, 95% confidence inter-
val = 1.07 to 18.45, P = 0.04). Tertiles of other biomarker
levels on ICU day 1 were not associated with 90-day mor-
tality (Table 4). We found similar findings when we ana-
lyzed the data using tests of trend across all three tertiles
(Figure 3).
Table 5 shows the unadjusted and multivariable-
adjusted odds ratios evaluating the associations between
ICU day 1 hCAP18 levels and hospital mortality, sepsis,
and incident AKI. We found significant associations be-
tween hCAP18 levels in the lowest and middle tertiles
and sepsis. We found no association between hCAP18
tertiles and hospital mortality or incident AKI.
Finally, we found no correlation between ICU day
1 hCAP18 levels and ventilator-free days (rs = −0.01,
P = 0.96). We found a nonsignificant trend between
hCAP18 levels and hospital-free days (rs = 0.16, P = 0.06),ors vs. nonsurvivors at 90 days. (A) Biomarker levels on ICU day 1.
ong survivors vs. nonsurvivors. Bars represent median (25th to 75th
timicrobial protein-18; ICU, intensive care unit; PTH, parathyroid hormone.
Table 4 Unadjusted and multivariable-adjusted odds ratios comparing ICU day 1 levels of hCAP18, 25D metabolites,
and PTH and risk of 90-day mortality
Outcome Unadjusted Adjusted
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
hCAP18
Tertile 1 4.80 (1.23-18.80) 0.02 4.49 (1.08-18.67) 0.04
Tertile 2 2.69 (0.64-11.23) 0.18 3.00 (0.67-13.25) 0.15
Tertile 3 (REF) 1.00 N/A 1.00 N/A
Total 25D
Tertile 1 1.41 (0.47-4.24) 0.54 1.39 (0.41-4.73) 0.60
Tertile 2 0.69 (0.21-2.40) 0.56 0.69 (0.19-2.56) 0.58
Tertile 3 (REF) 1.00 N/A 1.00 N/A
Bioavailable 25D
Tertile 1 0.97 (0.28-3.34) 0.96 1.11 (0.28-4.36) 0.88
Tertile 2 1.17 (0.35-3.88) 0.80 1.39 (0.36-5.34) 0.63
Tertile 3 (REF) 1.00 N/A 1.00 N/A
Free 25D
Tertile 1 1.45 (0.41-5.06) 0.56 1.47 (0.37-5.82) 0.59
Tertile 2 1.45 (0.41-5.06) 0.56 1.88 (0.44-8.05) 0.40
Tertile 3 (REF) 1.00 N/A 1.00 N/A
PTH
Tertile 1 1.00 (0.31-3.19) >0.99 1.22 (0.36-4.13) 0.75
Tertile 2 0.52 (0.14-1.95) 0.33 0.57 (0.15-2.25) 0.43
Tertile 3 (REF) 1.00 N/A 1.00 N/A
Twenty-one events. Adjusted models include age and APACHE II score. ICU, intensive care unit; hCAP18, human cathelicidin antimicrobial protein-18; 25D,
25-hydroxyvitamin D; PTH, parathyroid hormone; CI, confidence interval; APACHE II, acute physiology and chronic health evaluation II.
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in patients with higher hCAP18 levels.
Discussion
In this prospective cohort study among critically ill
patients, we found that lower total 25D levels were asso-
ciated with lower hCAP18 levels, which were in turn
associated with a greater risk of 90-day mortality. These
findings provide a potential mechanistic basis for the
commonly observed association between low 25D levels
and poor outcomes in critically ill patients.
The current findings expand on prior studies of vita-
min D metabolites and hCAP18. Preclinical studies have
demonstrated potent antimicrobial effects of hCAP18
against a broad range of pathogens [13-16,38-43]. Fur-
ther, the in vitro inducibility of hCAP18 by 25D and
1,25D has been demonstrated in multiple human cell
lines [10,18-22]. These preclinical studies are comple-
mented by numerous observational studies in humans,
which have consistently shown associations between
decreased 25D levels and increased mortality in patients
with critical illness [3-7] and in other settings [44-46].
The association between decreased 25D levels and ad-
verse outcomes in critical illness has been postulated tobe mediated, at least in part, by decreased production of
hCAP18 [6,47,48], yet few studies have simultaneously
measured 25D and hCAP18 and evaluated their associ-
ation with adverse outcomes. None, to our knowledge,
have done so in critically ill patients.
hCAP18 levels have been reported in critically ill
patients in only two other studies, neither of which
reported clinical outcomes. Jeng et al. found lower hCAP18
levels in critically ill patients (N = 49) compared to healthy
controls (N = 21) [25]. In a larger study (N = 130), no
difference in hCAP18 levels was detected among ICU
patients with vs. without sepsis [49]. A third study, which
was conducted among hemodialysis outpatients, reported
an inverse association between hCAP18 levels and 1-year
infection-related mortality [24]. Consistent with these
findings, we found associations between lower hCAP18
levels with both sepsis and 90-day mortality. Our findings
raise the possibility that inadequate circulating levels of
hCAP18, possibly due to decreased 25D levels, may pre-
dispose patients to infection and death. Consequently,
randomized controlled trials (RCTs) are warranted to test
whether administration of vitamin D metabolites may
increase hCAP18 levels and thereby improve outcomes in
critical illness.
Figure 3 Tertiles of plasma hCAP18, 25D metabolites, and PTH on ICU day 1 and risk of 90-day mortality. 25D, 25-hydroxyvitamin D; hCAP18,
human cathelicidin antimicrobial protein-18; ICU, intensive care unit; PTH, parathyroid hormone.
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vitamin D3 in 492 critically ill patients [50]. Although
the primary outcome of hospital length of stay was
negative, a prespecified analysis of patients with severe
vitamin D deficiency, defined as 25D levels ≤12 ng/ml,
found an almost 50% reduction in hospital mortality in
the active treatment group compared to placebo. hCAP18Table 5 Unadjusted and multivariable-adjusted odds ratios co
outcomes
Outcome Unadjusted
Odds ratio (95% CI)
Hospital mortality (9 events)
Tertile 1 2.17 (0.37-12.55)
Tertile 2 1.58 (0.25-10.00)
Tertile 3 (REF) 1.00
Sepsis (71 events)
Tertile 1 2.35 (0.96-5.74)
Tertile 2 3.72 (1.47-9.45)
Tertile 3 (REF) 1.00
AKI (33 events)
Tertile 1 0.65 (0.22-1.96)
Tertile 2 2.06 (0.78-5.45)
Tertile 3 (REF) 1.00
Adjusted models include age and APACHE II score. ICU, intensive care unit; hCAP18
kidney injury; APACHE II, Acute Physiology and Chronic Health Evaluation II.levels were not reported. In a pilot RCT of 67 cri-
tically ill patients with severe sepsis, we found that a
single dose of calcitriol (1,25D) increased hCAP18
leukocyte mRNA expression at 24 hours but did not
increase plasma levels [51]. Thus, additional RCTs
are needed to evaluate whether hCAP18 is inducible
in humans in response to vitamin D metabolites, as itmparing ICU day 1 hCAP18 levels and secondary
Adjusted
P value Odds ratio (95% CI) P value
0.39 1.97 (0.33-11.75) 0.46
0.63 1.66 (0.26-10.78) 0.60
N/A 1.00 N/A
0.06 2.54 (1.01-6.4) 0.047
0.006 3.64 (1.40-9.44) 0.008
N/A 1.00 N/A
0.45 0.61 (0.20-1.88) 0.39
0.15 2.01 (0.74-5.46) 0.17
N/A 1.00 N/A
, human cathelicidin antimicrobial protein-18; CI, confidence interval; AKI, acute
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outcomes.
We acknowledge the limitations of this study including
single-center, a maximum of two data points per patient,
and observational design. Although we measured DBP
and PTH, we did not measure all potentially relevant
markers of mineral metabolism such as 1,25D and fibro-
blast growth factor-23, nor did we measure all poten-
tially relevant markers of innate immunity, such as β
defensin 2, which may also be upregulated by vitamin D
metabolites [17]. Levels of bioavailable and free 25D
were estimated using equations that were not developed
and validated in critical illness. Therefore, estimated values
for these vitamin D metabolites should be viewed as pre-
liminary. Additionally, the association between hCAP18
levels on ICU day 1 and 90-day mortality could be con-
founded by a number of factors, such as severity of illness
or comorbidities. Importantly, this association remained
significant after adjusting for age and APACHE II score.
Nonetheless, residual confounding from other variables
cannot be excluded.
The association between hCAP18 levels and sepsis
should be viewed cautiously for a variety of reasons. First,
we did not have hCAP18 levels prior to the onset of acute
illness and therefore cannot exclude the possibility of re-
verse causality, since sepsis was assessed cross-sectionally.
Second, we cannot exclude the possibility of a type 1 error
due to multiple comparisons. Finally, although approxi-
mately half of all sepsis cases were due to a respiratory
infection, we did not find an association between hCAP18
levels and ventilator-free days, further suggesting that our
finding of an association between hCAP18 levels and
sepsis should be viewed as preliminary and in need of
confirmation.
Conclusions
In conclusion, our central findings are that lower total
25D levels on ICU day 1 are associated with lower
hCAP18 levels, which are in turn associated with a
greater risk of 90-day mortality. These data support the
notion that vitamin D metabolites may have important
effects on innate immunity via induction of hCAP18.
RCTs are needed to determine whether vitamin D metabo-
lites upregulate hCAP18 in humans, as they do in vitro,
and whether such a strategy will improve outcomes among
critically ill patients.
Key messages
 hCAP18 levels on ICU day 1 correlate positively
with total, but not bioavailable or free
25-hydroxyvitamin D levels.
 Lower hCAP18 levels on ICU day 1 are associated
with increased risk of 90-day mortality. Vitamin D metabolites may have important effects
on innate immunity via induction of hCAP18.
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Additional file 1: Supplemental methods. Calculation of bioavailable
and free 25-hydroxyvitamin D levels.
Additional file 2: Plasma hCAP18 levels on ICU day 1 and eGFR.
Plasma hCAP18 levels on ICU day 1 showed no correlation with eGFR.
Additional file 3: Plasma hCAP18 levels on ICU day 1 by (A) sepsis
severity, (B) primary site of infection, and (C) primary type of
organism.
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